Joseph Hayes, MD
Internal Medicine · Valdosta, GANPI 1952806846
Payments from drug & device makers
Across 80 payments — averaging $19.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$177
- GSK$173
- Amgen$141
- Pfizer$133
- AbbVie$121
- Novo Nordisk$103
- plus $705 from 18 others
What the payments were for
- Food & beverage$1,553100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 8 | $177 |
| GSK | 10 | $173 |
| Amgen | 9 | $141 |
| Pfizer | 6 | $133 |
| AbbVie | 5 | $121 |
| Novo Nordisk | 5 | $103 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $93 |
| Gilead | 3 | $80 |
| Exact Sciences | 4 | $76 |
| Dexcom, Inc. | 4 | $65 |
| AstraZeneca | 3 | $49 |
| Lilly USA, LLC | 3 | $49 |
| Axsome Therapeutics, Inc. | 2 | $45 |
| Otsuka America Pharmaceutical, Inc. | 2 | $37 |
| Smith+Nephew | 1 | $28 |
| Johnson & Johnson | 1 | $27 |
| Bayer | 1 | $23 |
| BD | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Corcept Therapeutics | 1 | $20 |
| Neurelis, Inc. | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Pulmonx Corporation | 1 | $18 |
| Shield Therapeutics Inc | 1 | $15 |
How this compares
$1,553 in reported general payments places this provider in the 70th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 166 | $209,747 |
| OzempicSemaglutide | 180 | $184,265 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 34 | $142,499 |
| JardianceEmpagliflozin | 83 | $81,389 |
| EliquisApixaban | 92 | $75,465 |
| EntrestoSacubitril/Valsartan | 58 | $55,713 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 74 | $52,456 |
| FarxigaDapagliflozin Propanediol | 60 | $51,246 |
| TrulicityDulaglutide | 37 | $40,500 |
| Tresiba Flextouch U-200Insulin Degludec | 29 | $30,631 |
| RexultiBrexpiprazole | 15 | $27,942 |
| LinzessLinaclotide | 23 | $20,861 |
| VraylarCariprazine Hcl | 11 | $17,754 |
| RybelsusSemaglutide | 15 | $17,003 |
| MyrbetriqMirabegron | 21 | $16,534 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $49 | $253,933226 claims |
| Novo NordiskOzempic, Rybelsus | $103 | $201,269195 claims |
| GileadBiktarvy | $80 | $142,49934 claims |
| PfizerEliquis | $133 | $75,46592 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $49 | $68,30094 claims |
| NovartisEntresto | $177 | $55,71358 claims |
| GSKTrelegy Ellipta, Shingrix | $173 | $55,47989 claims |
| AbbVieLinzess, Vraylar | $121 | $38,61634 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $37 | $27,94215 claims |
| Johnson & JohnsonXarelto | $27 | $8,54611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Valdosta
- Anna LedfordValdosta$108K
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.